Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer

A study to examine the efficacy and risk factors associated with pyrrotinib in the second- and third-line treatment of advanced breast cancer with Human epidermal growth factor receptor 2- (HER2-) positive cells was conducted. Progression-free survival (PFS) was assessed as the primary endpoint, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaolei, Huang, Yuxia, Yang, Zhen, Yang, Yang, Wei, Fenfen, Yan, Min, Li, Fanfan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509258/
https://www.ncbi.nlm.nih.gov/pubmed/36164613
http://dx.doi.org/10.1155/2022/7864114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509258/
https://www.ncbi.nlm.nih.gov/pubmed/36164613
http://dx.doi.org/10.1155/2022/7864114

Ejemplares similares